Skip to main content

Table 2 Comparison of comorbidity data between mild and severe NAFLD cohorts

From: Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease

  NAFLD (mild fibrosis) F0 to F2 ( n = 8) NAFLD (severe fibrosis) F3 to F4 ( n = 9) Statistical significance
Hypertension (N, %) 5 (62.5%) 4 (44%) ns
Any hypertensive medication (N, %) 5 (62.5%) 6 (66%) ns
T2DM (N, %) 8 (100%) 8 (100%) ns
Insulin treated (N, %) 3 (37.5%) 3 (33.3%) ns
Oral medication treated (N, %) 3 (37.5%) 7 (77.7%) ns
Diet treated (N, %) 2 (25%) 1 (11.1%) ns
Cardiovascular disease (N, %) 2 (25%) 2 (22.2%) ns
Dyslipidemia treated with lipid lowering agents (N, %) 4 (50%) 6 (66.6%) ns
1 Med (N, %) 3 (37.5%) 6 (66.6%) ns
>2 Meds (N, %) 1 (12.5%) 0 (0%) ns